Dual activation of GIP and GLP-1 receptors provides synergistic metabolic effects: enhanced insulin secretion, profound appetite suppression, improved fat oxidation, and effects on adipose tissue beyond GLP-1 alone.
Type 2 diabetes (Mounjaro), chronic weight management (Zepbound, BMI 30+ or 27+ with comorbidity).
MTC family history, MEN2, pancreatitis history, severe GI disease, pregnancy.
Unprecedented weight loss in Phase III — 22.5% mean reduction at 15mg. Demonstrated superiority over semaglutide in SURMOUNT-5.
- 1.Jastreboff AM et al., NEJM 2022 (SURMOUNT-1) — 22.5% weight reduction at 15mg, 96% achieved 5%+ loss. n=2,539, Phase III RCT
- 2.Aronne LJ et al., NEJM 2025 (SURMOUNT-5) — superior to semaglutide for weight reduction and waist circumference at 72 weeks
- 3.SHAPE Real-World, PMC 2025 — 16.5% vs 14.1% semaglutide at 1 year. n=9,916
- 4.Meta-Analysis, PMC 2025 — significantly superior to semaglutide (SMD: 0.75). n=28,980
Long-term cardiovascular outcomes trial (SURMOUNT-MMO) ongoing but not yet reported. Muscle mass preservation strategies needed.
MASH/NAFLD trials showing significant liver fat reduction. Sleep apnea improvement. Heart failure with preserved ejection fraction studies.